Inclusion Criteria:  Inclisiran Cohort Patients eligible for inclusion in this study must meet all of the following criteria.  Confirmed diagnosis of primary hypercholesterolemia or mixed dyslipidemia Age ≥ 18 years at baseline Initiated treatment with inclisiran according to the decision of both physician and patient Signed informed consent(s) must be obtained prior to participation in the study  SoC Historical Cohort Patients eligible for inclusion in this study must meet all of the following criteria.  Confirmed diagnosis of primary hypercholesterolemia or mixed dyslipidemia Age ≥ 18 years at baseline Under standard lipid lowering therapy  Exclusion Criteria:  Inclisiran Cohort Patients meeting any of the following criteria are not eligible for inclusion in this study.  Treatment with monoclonal antibodies directed towards PCSK9 within 90 days before first visit (V1) Severe hepatic impairment (Child-Pugh class C) Severe renal impairment (eGFR ≤ 30 mL/min), and/or on hemodialysis Participation in any cardiovascular clinical trial, concurrent or within the last 30 days of the baseline Females who are pregnant or nursing, or who are preparing for pregnancy Hypersensitivity to the active substance or to any of the excipients of inclisiran solution  SoC Historical Cohort Patients meeting any of the following criteria are not eligible for inclusion in this study.  Treatment with monoclonal antibodies directed towards PCSK9 Severe hepatic impairment (Child-Pugh class C) Severe renal impairment (eGFR ≤ 30 mL/min), and/or on hemodialysis Participation in any cardiovascular clinical trial during the period of data extraction sample size for the SoC Historical Cohort is sufficient to ensure appropriate matching based on the above estimates.